Last reviewed · How we verify
Anti-hypertensive Medication -
This anti-hypertensive medication lowers blood pressure through a mechanism that is not specified in the provided information.
Imperial College London is developing an anti-hypertensive medication with a novel mechanism of action, currently in various stages of clinical trials. The drug aims to improve blood pressure management, particularly in uncontrolled hypertension and specific patient populations such as the elderly and those with chronic kidney disease.
At a glance
| Generic name | Anti-hypertensive Medication - |
|---|---|
| Also known as | PR1 Diruetics, PR3 Beta Blockers, PR4 Calcium channel blockers, PR5 ACE inhibitors, PR6 Angiotensin II Receptor Blockers |
| Sponsor | Imperial College London |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Without the specific brand name or additional details, the exact mechanism cannot be determined. Anti-hypertensive medications work through various pathways including ACE inhibition, beta-blockade, calcium channel blockade, or vasodilation. Further information about the specific drug is needed to provide a precise mechanistic explanation.
Approved indications
- Hypertension
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-hypertensive Medication - CI brief — competitive landscape report
- Anti-hypertensive Medication - updates RSS · CI watch RSS
- Imperial College London portfolio CI